In a dramatic turn of events, Novo Nordisk has ended its partnership with Hims & Hers Health, citing concerns over illegal mass compounding practices and deceptive marketing related to Wegovy, a weight loss drug. This sudden termination has led to a significant drop in Hims & Hers stock, plummeting more than 30%. The fallout from this decision has initiated investigations into Hims & Hers, with potential legal implications for the company as investors express their worries regarding its future. CEO of Hims & Hers has publicly expressed disappointment, alleging that Novo Nordisk is misleading the public. The conflict between the two companies has raised questions about the legality of compounding and the ethics of marketing in the obesity treatment industry.